enGene Holdings Inc. (ENGN) Presents at Morgan Stanley 23rd Annual Global Healthcare

Judah Frommer
Equity Analyst

Welcome to the session of the Morgan Stanley Global Healthcare Conference. I’m Judah Frommer, one of the SMiD biotech analysts. We’re excited to have enGene joining us. And let me just go through a quick disclosure before welcoming Ron.

For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. So again, thank you for being here. Maybe we just start out for those less familiar with the enGene story. Can you provide a brief introduction to the company and your lead asset?

Ronald H. Cooper
President, CEO & Director

Well, first of all, thanks very much for the opportunity to be here. We really appreciate it. So enGene is a company that has nonviral gene therapy. And that is unique, unique. So when you first of all, when you think about gene therapies, you think about some of the shortcomings of gene therapies. But in fact, by delivering gene therapy through the mucosa using our Special DDX platform, we’ve been actually able to solve some of those issues.

So first of all, we’re able to give a big genetic cargo. We’re not limited by cargo. Our products are redoseable, and we can use them over and over again as needed. And because it’s nonviral, our manufacturing is a lot simpler, right? So our cost of goods should be competitive, which allows us to get to many more diseases. So I think we sort of cracked the code in some of the challenges of gene therapy.